Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PHENCYCLIDINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources

Prenatal phencyclidine induces heightened neurodegeneration in rats in some brain regions, especially during 2nd trimester, but possible anti-apoptotic effects in others.

Phencyclidine administered to the developing rat brain at high doses for a few hours during late foetal life induces apoptotic neurodegeneration in several brain regions. We sought to investigate whether prolonged, low level foetal exposure to phencyclidine during different gestational periods (2nd trimester versus 3rd trimester) would have different effects on several brain regions showing neurodegeneration as assessed using silver stains. Pregnant rats were treated with phencyclidine (5.45 mg/day) continuously for 5 days via minipumps, and the pups were either perfused immediately after birth and silver-stained for degeneration, or allowed to mature and then tested for behavioural deficits. In the newborn pups, there was a substantial increase in the number of agrophilic cells in entorhinal cortex and subiculum; this effect was greater when the drug was given during 2nd trimester. However, in the ventromedial nucleus of the hypothalamus, both the 2nd and 3rd trimester phencyclidine pups had significantly fewer degenerating cells than the controls. Behavioural tests of rotorod and open field performance in the pups allowed to mature indicated decreased motor coordination and hyperactivity in the 3rd trimester phencyclidine pups, but minimal alterations in the 2nd trimester pups. Thus, prenatal exposure to phencyclidine can have either neurodegenerative or antiapototic effects depending upon brain region, and there is a discrepancy between persisting behavioural deficits and amount of cell loss for time of maximal prenatal effect of the drug.

Analysis of Variance↗

Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes.

[3H]Phencyclidine binds to synaptic membranes from rat brain in a saturable, reversible, and selective fashion, with a dissociation constant Kd of 0.25 microM and a maximal binding capacity of 2.4 pmol/mg of membrane protein--i.e., 250 pmol/g of brain. The binding activity is concentrated in synaptosomal fractions, is higher in cerebral cortex and corpus striatum than in other parts of the rat brain, and is not detectable in the spinal cord. Only molecules of the phencyclidine series and ketamine are able to bind to the phencyclidine receptor. [3H]Phencyclidine bound to its receptor is not displaced by the classical neurotransmitters or neuromodulators. There is a good correlation between the apparent affinities of a series of phencyclidine analogs for the phencyclidine receptor and the pharacological activities of these analogs as measured by the rotarod assay.

Animals↗

Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication.

Phencyclidine concentrations were measured in the plasmas of 22 patients with nonfatal phencyclidine intoxication using gas-liquid chromatography with a nitrogen detector. Concentrations found ranged from less than 10 to 812 micrograms/l, and except for the systolic blood pressure (r = 0.60, P less than 0.05), showed no significant correlation with the physical findings. The most common physical findings were combativeness-agitation (64%), depressed level of consciousness (50%), hypertension (43%), moiosis (43%), and tachycardia (43%). Phencyclidine concentrations measured in the erythrocytes of seven of the patients were generally higher than concentrations in the corresponding plasmas (erythrocyte:plasma concentration ratios ranged from 3.1 to 37.9), suggesting that the binding of phencyclidine to plasma proteins is low. Erythrocytic concentrations also showed no significant correlation with either the physical findings or the plasma concentrations of phencyclidine. For 15 unselected urines the concentrations of phencyclidine showed no significant correlation with urinary pH.

Adolescent↗

Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia.

Clinical and laboratory findings suggest that cannabinoid signalling is implicated in schizophrenia. However, the interaction remains poorly understood, as data are often contradictory. Here we investigated wild-type (WT) and cannabinoid CB1 receptor-knockout (CB1-KO) mice in the phencyclidine-induced social withdrawal model of schizophrenia. N-methyl-D-aspartate (NMDA) antagonists (including phencyclidine) induce psychotic symptoms in humans, and are used to model schizophrenia in a variety of experimental conditions. In WTs, 5 mg/kg phencyclidine increased locomotion and stereotyped behaviours, and decreased social interactions. These changes are consistent with a schizophrenia-like effect. In CB1-KOs, phencyclidine decreased locomotion, enhanced ataxia and stereotypy more markedly than in WTs, but did not affect social interactions. Locomotion showed a significant negative correlation with both ataxia and stereotypy, suggesting that in CB1-KOs, the locomotor suppressive effect of phencyclidine was secondary to changes in these variables. Our findings demonstrate that CB1 gene disruption dramatically alters the behavioural effects of the NMDA antagonist phencyclidine, suggesting that the CB1 receptor is involved in schizophrenia. As social disruption and stereotypy respectively are believed to model negative and positive symptoms of schizophrenia, our findings tentatively suggest that cannabinoids are differentially involved in these two symptom categories. These findings require verification by experiments involving CB1 receptor blockers, as the genetic and pharmacological blockade of receptors may not always provide similar results.

Animals↗

Phencyclidine use among youth: history, epidemiology, and acute and chronic intoxication.

Phencyclidine use appears to be in a growth phase nationally. Factors contributing to the increasing popularity include the user's ability to control the dosage, an understanding of the immediate effects, and its availability. Those most at risk appear to be young Caucasian males. Phencyclidine-related problems are often like tips of icebergs, the underlying causes of which are hidden from public view. The problems often surface in the form of speech difficulties, memory loss, thinking disorders, personality changes, paranoia, severe depression, violence, accidents, suicides and homicides. Of particular concern to law enforcement personnel is the upsurge in phencyclidine-related violent crimes and carrying of weapons by users to protect themselves from their imagined persecutors. The evidence currently available supports the assumption that if there is a solution to the problem of phencyclidine abuse, that solution is prevention. Therefore, medical personnel and others within the helping professions must be alerted to the fact that phencyclidine is not just another drug problem. The findings from users we have already studied strongly suggest that phencyclidine is not an "upper" or a "downer," but perhaps an "insideouter", with longer term implications.

Adolescent↗

Preliminary observations of the effects of phencyclidine in decomposing tissues on the development of Parasarcophaga ruficornis (Diptera: Sarcophagidae).

Larvae of Parasarcophaga ruficornis (Fabricius) (Diptera: Sarcophagidae) were reared on tissues from rabbits administered different dosages of phencyclidine to study the effects of this drug on the development of this insect species. The rabbits were given 3.66, 7.31, and 14.62 mg of phencyclidine via ear vein infusion. No significant differences in larval growth rate were observed among the colonies, although the duration of the non-feeding portion of the third instar was shorter for larvae fed on tissues containing the drug. Mortality during the larval stage was directly related to the dosage of phencyclidine administered, ranging from 0 in the control colony to 29.0% in the colony fed on tissues from the rabbit receiving 14.62 mg of phencyclidine. Durations of the puparial stage were longer for colonies fed on tissues containing the drug. Presence of phencyclidine was detected in larvae from all colonies fed on tissues from rabbits receiving the phencyclidine using GC/MS.

Animals↗

Application of a radioimmunoassay screening test for detection and management of phencyclidine intoxication.

A radioimmunoassay procedure has been developed to monitor patients suspected of phencyclidine (PCP) intoxication. Symptoms in 11 patients suspected of phencyclidine intoxication included violent, aggressive behavior with delusions, hallucinations, agitation, and other signs of toxic psychosis. In five subjects serum concentrations of PCP ranged between 0.5 and 40 ng/ml. For laboratory confirmation, ascorbic acid should be administered to the patient after collecting the initial urine specimen. The initial urine and the first and second specimen after acidification should be collected and submitted for analysis. By following this provocative mobilization procedure, phencyclidine has been identified in the first or second postacidification urine when the initial specimen gave either a negative or questionable reaction. Patients reporting to emergency rooms with hallucinations and psychosis and a history of "pot" smoking should be screened for the presence of phencyclidine in their blood and urine. For those cases that turn out to be negative for the phencyclidine group of compounds, other hallucinogenic drugs such as lysergic acid diethylamide, ketamine, mescaline, or psilocybin may be suspect.

Adolescent↗

Wash-resistant inhibition of phencyclidine- and haloperidol-sensitive sigma receptor sites in guinea pig brain by putative affinity ligands: determination of selectivity.

Several putative affinity ligands, based on the structures of phencyclidine etoxadrol, 5-methyl-10,11-dihydro-5H-dibenzo[a,d] cycloheptene-5,10-imine (MK801) and 1,3-di-(2-methylphenyl)guanidine (DTG) were evaluated in vitro for their ability to produce a wash-resistant inhibition of phencyclidine and sigma receptor sites in homogenates of the brain of the guinea pig. All the phencyclidine-based ligands, including 1-[1-(3-isothiocyanatophenyl)cyclohexyl]piperidine (Metaphit) and (+/-)-N-(2-isothiocyanatoethyl) MK801 [(+/-)-MK801-NCS], produced a wash-resistant inhibition of binding sites for phencyclidine, labelled by [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP) and sigma binding sites, labelled by [3H]DTG. The DTG-based ligands, 1-(4-isothiocyanato-2-methylphenyl)-3-(2-methylphenyl)guanidine (DIGIT) and 1-(4-[2-(2-isothiocyanatoethoxy)ethoxy]-2-methyl-phenyl)-3-(2- methylphenyl)guanidine (DIGIE), produced a wash-resistant inhibition of sigma sites, at concentrations as small as 1 microM and also inhibited binding sites for phencyclidine at larger concentrations (100 microM). Both 1-(3-isothiocyanatophenyl)-1-ethyl-4-(2-piperidyl)-1,3-dioxolane (ETOX-NCS) and 1-[1-(3-bromoacetyloxyphenyl)cyclohexyl]-1,2,3,6-tetrahydropyri din e (Bromoacetyl-PCP) were the most potent and selective inhibitors of the binding of [3H]TCP, while DIGIT was the most selective inhibitor of the binding of [3H]DTG. Future studies will examine the selectivity of these agents in vivo after intracerebroventricular administration.

Affinity Labels↗

Neonatal manifestations of maternal phencyclidine exposure.

The purpose of this study was to determine the effects of maternal phencyclidine use on the fetus. Ninety-four neonates with maternal phencyclidine exposure were compared with 94 controls. Maternal phencyclidine use was assessed by questionnaire and repeated urine testing. Mothers of study and control patients were matched for demographic characteristics. Infants were assessed between 24-72 hours postnatally by a single examiner blind to the maternal history. The results showed that study infants had a mean of 5.02 +/- 2.93 abnormalities while controls had a mean of 4.13 +/- 2.65 abnormalities (p less than 0.01). Furthermore, study infants were more likely than controls to have poor attention, hypertonia, and depressed neonatal reflexes (p less than 0.05). The contribution of seven drug classes to the total number of abnormalities was assessed using stepwise multiple regression. Only phencyclidine accounted for a significant proportion of the variance (f = 4.38; p less than 0.05). The results of this study suggest that maternal phencyclidine use may lead to abnormal neonatal neurologic findings and behavior.

Abnormalities, Drug-Induced↗

[Phencyclidine--angel dust].

BACKGROUND: For the first time in ten years, phencyclidine (PCP) has been confiscated in Norway. Physicians should be aware of this substance when treating intoxications. METHODS: Relevant literature was identified by search in Medline. This review presents the pharmacological properties and effects of phencyclidine as well as symptoms and treatment of phencyclidine intoxication. RESULTS AND INTERPRETATION: Phencyclidine exhibits hallucinogenic, depressant and stimulant properties. Phencyclidine interacts as an antagonist to the N-methyl-D-aspartate (NMDA) receptor in the central nervous system. Severe NMDA receptor hypofunction can elicit clinical symptoms similar to a schizophrenic episode.

Diagnosis, Differential↗

The role of isometric muscle tension in the production of muscle toxicity by phencyclidine and restraint stress.

A restraint cage with a strain gauge attached to a movable roof to record the isometric force exerted by rats during restraint is described. The isometric activity score, an integral of the total upward force exerted during restraint, correlated significantly with plasma creatine phosphokinase (CPK) activity in rats following restraint. Phencyclidine 5 mg/kg administered intraperitoneally to rats 15 min prior to 1/2 hr restraint has been shown to produce muscle damage associated with large increases of plasma CPK activity. Dose-response curves for the effects of phencyclidine on isometric activity score and plasma CPK activity were essentially parallel, and isometric activity scores were linearly related to plasma CPK activity. Rats restrained and painfully stimualted on the tail developed both elevated isometric activity scores and elevations of plasma CPK activity. Slopes of the curves relating isometric activity to plasma CPK activity were identical for painfully stimulated and phencyclidine treated rats. Phencyclidine has been reported to produce large increases in locomotor activity. Thus, increased isometric muscle tension developed during phencyclidine plus restraint is related to the production of muscle damage and increased efflux of CPK in rats.

Animals↗

Molecular environment of the phencyclidine binding site in the nicotinic acetylcholine receptor membrane.

Phencyclidine is a highly specific noncompetitive inhibitor of the nicotinic acetylcholine receptor. In a novel approach to study this site, a spin-labeled analogue of phencyclidine, 4-phenyl-4-(1-piperidinyl)-2,2,6,6-tetramethylpiperidinoxyl (PPT) was synthesized. The binding of PPT inhibits 86Rb flux (IC50 = 6.6 microM), and [3H]phencyclidine binding to both resting and desensitized acetylcholine receptor (IC50 = 17 microM and 0.22 microM, respectively). From an indirect Hill plot of the inhibition of [3H]phencyclidine binding by PPT, a Hill coefficient of approximately one was obtained in the presence of carbamylcholine and 0.8 in alpha-bungarotoxin-treated preparations. Taken together, these results indicate that PPT mimics phencyclidine in its ability to bind to the noncompetitive inhibitor site and is functionally active in blocking ion flux across the acetylcholine receptor channel. Analysis of the electron spin resonance signal of the bound PPT suggests that the environment surrounding the probe within the ion channel is hydrophobic, with a hydrophobicity parameter of 1.09. A dielectric constant for the binding site was estimated to be in the range of 2-3 units.

Animals↗

Situational specificity of tolerance to effects of phencyclidine on responding of rats under fixed-ratio and spaced-responding schedules.

Responding of rats (n = 5) was maintained under DRL (lever) and Time-Delay (nose-key) schedules of food presentation in different experimental chambers during two separate daily sessions. Tolerance that developed to rate-decreasing effects of phencyclidine for nose-key pressing under the Time-Delay schedule did not extend to effects of phencyclidine on lever pressing under the DRL schedule. In a second experiment, both lever and nose-key pressing of rats were maintained under individual and multiple fixed-ratio schedules. One group of animals (n = 5) experienced both the individual and the multiple schedules in the same experimental chamber and another group (n = 5) experienced the individual and the multiple schedules in different experimental chambers. Tolerance that developed to behavioral effects of phencyclidine during the individual schedule did not extend to responding on even the same manipulandum under the multiple schedule in a different experimental chamber. In contrast, tolerance that developed to behavioral effects of phencyclidine during the individual schedule did extend to responding on even the different manipulandum under the multiple schedule in the same experimental chamber. Thus, tolerance that developed in the environment that was coincident with the pharmacologic actions of phencyclidine did not extend to similar operants in a different environmental condition, but did extend even to a different operant and schedule context in the same environmental condition.

Animals↗

Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat.

The ability of the nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), to block the behavioural effects of the potent psychotomimetic, phencyclidine, was tested in rats using two different behavioural models. L-NAME was found to block both phencyclidine-induced disruption of prepulse inhibition of acoustic startle and phencyclidine-induced stimulation of locomotor activity. A selective action of L-NAME on the effects of phencyclidine was indicated, since L-NAME did not alter the effects of amphetamine, another potent psychotomimetic, in these behavioural models. These observations suggest that a nitric oxide-dependent mechanism may be involved in the effects of phencyclidine in the central nervous system.

Animals↗

Evaluation of the efficacy of antipsychotic attenuation of phencyclidine-disrupted prepulse inhibition in rats.

SUMMARY: Phencyclidine reliably disrupts prepulse inhibition of the acoustic startle response in rats. Previous research has suggested that atypical antipsychotics (e.g., those that do not produce extrapyramidal motor effects) attenuate the disruptive effects of phencyclidine in this model whereas typical antipsychotics do not. Nearly all of this research has used the D2 antagonist haloperidol for comparison. In this study, antipsychotics with more diverse receptor binding profiles were tested for their efficacy in attenuating phencyclidine-induced disruption of prepulse inhibition. Results showed that phencyclidine disrupted prepulse inhibition in all groups of rats. Olanzapine, but not clozapine, attenuated this disruption, but this effect occurred only at a single (5 mg/kg) dose. None of the other antipsychotics nor spermine altered phencyclidine's effects. These results suggest that this model does not reliably differentiate between typical and atypical antipsychotics.

Animals↗

Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism.

Various compounds that have been identified in the literature as binding to the [3H]phencyclidine receptor site and as producing behavioral effects similar to phencyclidine (phencyclidine-like) protected mice from maximal electric shock-induced tonic-extensor seizures. These anticonvulsant effects appear to be due to blockade of the N-methyl-D-aspartic acid receptor, as recently reported for phencyclidine-like compounds. Phencyclidine-like compounds produced their anticonvulsant effects at doses that were also neurologically impairing.

Animals↗

The effects of ketamine, phencyclidine and lidocaine on catecholamine secretion from cultured bovine adrenal chromaffin cells.

The ability of ketamine, phencyclidine and analogues to alter catecholamine secretion from cultured bovine adrenal chromaffin cells was investigated. Both ketamine and phencyclidine specifically inhibited nicotinic agonist-induced secretion at concentrations which did not alter secretion induced by elevated K+ depolarization. The inhibition of nicotinic agonist-induced secretion was not overcome by increasing concentrations of nicotinic agonist. The effects of stereoisomer pairs of phencyclidine-like drugs - dexoxadrol, levoxadrol and (+)PCMP, (-)PCMP - did not reveal stereospecificity for the inhibition, in contrast to the stereospecific behavioral effects of the drugs. The local anesthetic lidocaine (0.3 mM) also noncompetitively inhibited nicotinic agonist-induced secretion without inhibiting elevated K+-induced secretion. The data indicate that ketamine and phencyclidine at clinically relevant concentrations specifically inhibit the adrenal chromaffin cell nicotinic receptor at a site similar to or identical with the site of action of local anesthetic. Although the nicotinic receptor inhibition is probably not related to the anesthetic and behavioral effects of ketamine and phencyclidine, it is likely that the centrally mediated increase in sympathetic nervous system activity which is characteristic of these drugs is moderated by the peripheral blocking effects on catecholamine secretion from the adrenal medulla.

Adrenal Medulla↗

Effects of phencyclidine and ketamine on cardiovascular activity and temperature in the squirrel monkey.

Heart rate (HR), mean arterial blood pressure (BP) and core temperature (TEMP) were recorded from chair-restrained squirrel monkeys surgically prepared with chronically indwelling arterial and venous catheters to determine the effects of acute intravenous (i.v.) injections of phencyclidine and ketamine and intramuscular (i.m.) injections of ketamine. Phencyclidine (0.03-3.0 mg/kg) and ketamine (0.3-30.0 mg/kg) i.v. increased BP and decreased TEMP, and the changes in BP and in TEMP were greater in magnitude and duration after phencyclidine. Heart rate also increased monotonically after 0.03-0.3 mg/kg phencyclidine or 0.3-10.0 mg/kg ketamine, but the effects of higher doses of either drug were biphasic with decreases followed by increases in HR. When either of two doses of ketamine (10.0 and 30.0 mg/kg) was injected i.m., the effects were qualitatively similar to those observed after i.v. administration although of much less magnitude, and there was no evidence of a biphasic change in HR. The data show that these two dissociative anesthetics differ in duration of action and in magnitude of effect on cardiovascular activity and core temperature in the squirrel monkey, and that phencyclidine is approximately ten times as potent as ketamine.

Animals↗